IUSV: VLUE And FVAL May Be More Compelling

The iShares Core S&P U.S. Value ETF charges a low 0.04% expense ratio and broadly tracks the Russell 1000 Value benchmark over the long term, but it has lagged by 6% over the past year. Competitors VLUE and FVAL have outperformed IUSV since 2016, with the article attributing their edge to cash-flow-based valuation and sector-specific methodologies. The piece is mainly comparative ETF analysis and is unlikely to drive broad market moves.

Analysis

The relative underperformance of a broad, low-cost value wrapper versus more rules-driven competitors suggests this is less about “value” as a factor and more about what kind of value investors are being forced to own. Broad cap-weighted value portfolios tend to drift toward the most obvious balance-sheet and dividend names, which can become crowded, lower-beta holdings that lag when the market rewards free-cash-flow quality, pricing power, and index reconstitution effects. In that sense, the gap versus alternatives is likely a reflection of methodology alpha, not a verdict on the value factor itself.

The second-order winner is active and semi-systematic value exposure that screens for cash generation and sector tilts, because those approaches can avoid the classic value traps embedded in cheap-but-stagnant industrials, banks, and mature consumer names. If this persists, the pressure will not just hit IUSV-like vehicles; it will also bleed into institutions benchmarking to broad value indices, forcing incremental flows into smarter factor products and amplifying the crowding differential. That creates a feedback loop: the more investors chase the better-performing methodology, the more the broad basket becomes a “left behind” residual of cheaper but lower-quality names.

The key risk to fading this move is regime rotation. If rates fall faster than expected and cyclical/financial earnings reaccelerate, the broad value basket can snap back over a 3–6 month horizon because it has more embedded beta to the classic reopening/value rebound than the quality-tilted alternatives. Conversely, if growth stays resilient and the market keeps rewarding earnings durability over cheapness, the relative underperformance can persist for multiple quarters, making this a structural rather than tactical issue.

Consensus seems to be treating all value ETFs as interchangeable; that is the miss. Investors are underestimating how much the factor premium now depends on implementation details, and broad value may be the least efficient expression of the theme in a market where dispersion within sectors matters more than sector rotation alone. The most likely path is not a dramatic collapse in absolute returns, but continued relative leakage versus more selective competitors.

Key Decisions for Investors

• Prefer VLUE or FVAL over IUSV for new value allocations over the next 1–3 months; the better screening methodology offers a cleaner shot at relative outperformance with limited additional factor risk.
• Pair trade: long VLUE / short IUSV for a 3–6 month horizon. Theses are closely related exposures, so the spread should be driven mainly by methodology, not market direction; target a modest but persistent relative return differential if factor dispersion stays high.
• If using IUSV as a benchmark hedge, reduce sizing by 20–30% and replace with a blend of quality-value and sector-tilted value exposures to avoid owning the lowest-conviction names in the basket.
• Monitor rates and financials/cyclicals breadth: if the 2s10s curve steepens and cyclicals leadership broadens, add to broad-value exposure tactically for a 1–2 quarter mean-reversion trade.
• Avoid buying IUSV as a passive substitute for active value until relative performance stabilizes for at least two consecutive months; the current setup favors methodology alpha, not blanket factor exposure.